相关实验视频

Updated: Jun 7, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

肠道微生物群和与广泛阶段小细胞肺癌免疫治疗疗效相关的代谢物:试点研究

Liyang Sun¹, Xueting Wang¹, Huimin Zhou¹

¹Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.

Journal of thoracic disease

|November 18, 2024

概括

肠道微生物群的多样性在扩展阶段小细胞肺癌患者中增加,这些患者对免疫治疗有反应. 特定的细菌和短链脂肪酸与治疗反应有关,为免疫检查点抑制剂提供了潜在的生物标志物.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
微生物组研究微生物组研究

背景情况:

肠道微生物群影响免疫反应和免疫疗法的有效性.
广泛阶段小细胞肺癌 (ES-SCLC) 患者的肠道微生物组和代谢物被调查以检查免疫疗法相关性.

研究的目的:

探索肠道微生物群,代谢物和ES-SCLC患者的免疫治疗疗效之间的关系.
为了确定预测治疗反应的潜在生物标志物.

主要方法:

49名ES-SCLC患者的便样本被用抗PD-L1抗体治疗,在治疗前和治疗后进行分析.
使用16SrRNA测序和非向代谢学 (LC-MS) 来识别肠道微生物群和代谢物.
在响应者和非响应者之间比较了微生物组组成和代谢物概况.

主要成果:

在响应者 (R) 和非响应者 (NR) 之间没有观察到肠道微生物群多样性的显著基线差异.
在治疗后,响应者表现出明显更高的α多样性和丰富的*Faecalibacterium*,*Clostridium_sensu_stricto_1*,和*[Ruminococcus]_torques*.
短链脂肪酸 (SCFA) 在响应者中被上调,与PD-L1/PD-1信号通路相关的差异性代谢物.

结论:

肠道微生物群的组成和多样性变化与ES-SCLC的免疫治疗反应相关.
特定的微生物种群和SCFA可以作为免疫检查点抑制剂 (ICI) 疗效的预测生物标志物.
这些发现为了解ES-SCLC免疫治疗的分子机制提供了新的途径.

关键词:

小细胞肺癌 (SCLC) 是一种癌症.化学疗法化疗化疗我们的肠道微生物群.免疫疗法免疫疗法代谢生物组的代谢生物组

更多相关视频

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System

Published on: August 30, 2019

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...